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A Ab bs st tr ra ac ct t
The search for a genetic basis for schizophrenia has taken a new turn recently with the publication
of three reports of various rare copy-number variations that are associated with schizophrenia.
While some of the findings may simply disappear as spurious reports, others remain interesting:
that is, deletions in the Velocardiofacial syndrome region of chromosome 22, and regions of
chromosome 1q21.1 and 15q13.3. These results will gain greater significance if future validation in
family studies shows their segregation with illness within families, and when it is understood how
the genes containing these variants affect the underlying neurochemistry and neuropathology
characteristic of schizophrenia.
I In nt tr ro od du uc ct ti io on n
Development into adulthood has, at its origins, strands of
DNA inherited from two parents combined with endogenous
or external environmental influences. Which aspect of this
input is most crucial for development is not well understood.
Yet it is well known now that siblings or twins adopted away at
birth share very similar physical, personality and mental traits
with their close biological relatives [1]. On the other hand, it is
also known that changing the prenatal and perinatal
environment of a fetus and infant can have a long-lasting
effect on the developed adult and even their offspring [2].
It is in this context that we try to unravel the genetic mecha-
nism that leads to high risk for schizophrenia, particularly
given the last decade of progress that has led us into a new
era of human genome research. Early genetic studies ([3];
reviewed in [4]) led to several false starts and inconsistent
chance findings of gene variants associated with schizo-
phrenia and linkages to specific chromosomal regions. These
studies culminated in the presence of over 2,000 reports in
the current literature examining allelic associations to schizo-
phrenia and well over 50 genes that are claimed to have
positive associations. In fact, almost every chromosome arm
has a reported linkage to schizophrenia (reviewed in [4-6]).
T Th he e   i in nh he er ri it ta an nc ce e   a an nd d   g ge en ne et ti ic c   m me ec ch ha an ni is sm m   o of f
s sc ch hi iz zo op ph hr re en ni ia a
Schizophrenia is a lifetime brain disorder detectable in late
adolescence to early adulthood that particularly affects the
higher cortical centers for complex learning, memory and
communication with others. People with this illness
frequently hear disturbing voices that are not there and have
multiple delusionary perceptions that prevent them from
functioning in society on a daily basis. It has long been
established through epidemiological studies of families, twins
and adoptees to be highly heritable. However, its inheritance
does not follow any Mendelian pattern. Once schizophrenia
had been accepted as one of the so-called ‘complex’ genetic
disorders and it had become clear that simple methods that
were useful for studying the inheritance of Mendelian
disorders were not leading to clear candidate genes, other
study designs came into fashion. These included examination
of differential patterns of inheritance for imprinting and
anticipation effects [7-10], examining linkage in genetically
isolated cohorts [11-14], and searching for ‘intermediate
phenotypes’ or ‘endophenotypes’ [15,16] to use as alternative
variables in linkage analyses. None of these have yet been
successful in definitively finding a gene defect linked to
schizophrenia. General conclusions from the literature are
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© 2009 BioMed Central Ltd that (i) neither imprinting nor anticipation have major roles
in schizophrenia genetics; (ii) the genetic isolate studies thus
far have not yielded any findings that are clearly different
from the studies on heterogeneous outbred populations; and
(iii) no endophenotype has currently been found that seems
to be more heritable than the clinical diagnosis of
schizophrenia itself. Nevertheless, there can be optimism for
future progress towards uncovering a genetic mechanism for
schizophrenia because of the parallel and rapid progress in
the field of molecular genetics and the recent discoveries of
novel genetic processes.
It remains clear from consistent and accepted observations
among clinicians that schizophrenia clusters heavily in some
families, whereas in others it seems to be a sporadic
occurrence; sometimes it appears in two successive genera-
tions, frequently without having occurred in previous
generations, and thus it seems more horizontal in inheri-
tance than vertical in these cases. There are a few speculative
hypotheses that emerge from these observations: (i) that
environmental effects on gene expression could be a key
[17]; (ii) that other epigenetic effects on expression of genes,
perhaps endogenous effects (effects within ones own body),
may be taking place [18]; or (iii) that there are many rare
variants that occur by deletions or insertions in active
regions of crucial genes, and that these may lead to schizo-
phrenia, having a major effect in specific families or simply
occurring sporadically [19].
C Co op py y   n nu um mb be er r   v va ar ri ia at ti io on ns s
The hypothesis that rare variants of crucial genes have a role
in schizophrenia has received much attention recently in
three major publications of genome-wide copy-number
variations (CNVs; Table 1) [20-22] and at least one specifi-
cally examining copy number in several candidate genes
[23]. These papers were preceded by success in locating
some pathological CNVs consistently associated with autism
(for example, [24]). If CNVs are relevant to autism, it is a
reasonable assumption that they could be important in other
major serious mental illnesses. Following this logic, Walsh
and colleagues [20] published an initial finding on a rela-
tively small set of two US cohorts, one a clinic population
from the Northwestern USA and the other a tertiary referral
population of unusual childhood onset cases. Tertiary refer-
ral in this case means another doctor has referred the case,
usually because it is a difficult case that does not respond to
the usual treatments. In both cohorts the number of large
deletions was significantly greater in the patient groups than
in controls, but no one deletion or mutation stood out.
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Study Number of subjects Geographical locations Laboratory methods Results
Stefansson  1,433 patients with  England, Finland, Germany,  High-density SNP  Deletions at chromosomes 1q21.1, 15q11.2 and 
et al. [21] schizophrenia; 33,250  Iceland, Italy and Scotland  microarrays 15q13.3 associated with schizophrenia (findings 
controls. Follow-up with  in bold are those that are present in more than 
3,285 cases and 7,951  1 study) 
controls
The Inter- 3,391 patients with  Several sites: Bulgaria,  High-density SNP  1.15x increase in schizophrenia for CNVs 
national  schizophrenia (according  England, Ireland, Portugal  microarrays greater than 100 kb and in less than 5% of the 
Schizophrenia  to the DSM-IV or ICD-10  (Azores), Scotland and  sample. Deletions found in the VCSF region on 
Consortium definitions†); 3,181  Sweden chromosome 22, ad in chromosomes 15q13.3 
[22]* ancestrally matched controls and 1q21.1 
Walsh et al. 150 patients with  USA (various locations)  CGH screen (85,000  Novel deletions and duplications present in 15% 
[20] schizophrenia; 268  probe arrays initially,  of adult and 20% of COS patients versus 5% of 
ancestrally matched controls and an Illumina 550  controls. No one of these specifically associated 
array for validation to  with schizophrenia. In COS deletions in 2q31.2, 
identify microdeletions  2p16.3 (NRXN1 gene), 16p11.2 were associated
greater than 100 kb)
Sutrala et al. 85 unrelated Caucasians  England and Ireland  CGH screen with  CGH screen yielded CNVs in six genes, but no 
[23]* with schizophrenia  oligonucleotide probes  excess in schizophrenia. No CNV was found by 
(DSM-IV definition); control  of 891 candidate genes,  either method to be in excess in schizophrenia
DNA was from the CEPH† then allele quantification 
collection  by DNA pooling for 
15 genes 
*There is an overlap in authorship and perhaps a minor overlap in samples between these papers and [21]. †Abbreviations: CEPH, Centre d’Etude du
Polymorphisme Humain genotype database; CGH, comparative genomic hybridization; COS, childhood onset; DSM-IV, Diagnostic and Statistical Manual
of Mental Disorders, 4th Edition; ICD-10, WHO International Classification of Diseases; SNP, single nucleotide polymorphism; VCFS, velo-cardio facial
syndrome.This study [20] was only a very preliminary attempt to
confirm the same group’s past speculation that the genetic
basis for schizophrenia is multiple rare mutational events,
perhaps in genes of relevant neuronal pathways [19]. Most
recently, the work of Walsh and colleagues [20] was followed
by two highly publicized multicenter large international
combinations of cohorts that both examined whether CNVs
were more prevalent in schizophrenia than would be expec-
ted by chance [21,22]. Although increases in CNVs were
suggested, overall the amount of excess was minimal (1.14 in
one report [22]) and only mentioned as ‘nominal’ in the
other [21] but clearly less than the over three-fold increase
observed by Walsh and colleagues [20] studying a much
smaller cohort. Sutrala and colleagues [23] in the UK
studied CNVs using a similar comparative genomic hybridi-
zation method to that used in the other studies [20], but
with oligonucleotide probes rather than the bacterial artifi-
cial chromosome (BAC) clones, and they were thus able to
detect smaller deletions than those found in the previous
studies. They did not do a whole genome-wide screen, how-
ever, but rather focused on sequences in 891 different
candidate genes, and they failed to find any associations with
schizophrenia. Thus, if rare mutational events account for
the genetics of schizophrenia, this is likely to be only a minor
contributing mechanism and will not explain the majority of
the inheritance of schizophrenia.
Although in some instances consistent CNV findings have
emerged that seem to be interesting (such as chromosomes
1q21.1 and 15q13.3, which have associated deletions in two
studies [21,22] or the uncovering of a CNV in the region
associated with velo-cardio facial syndrome (VCFS) [22],
which is frequently implicated in schizophrenia), other find-
ings might not be replicated, or their locations might not be
consistent with any gene that is known to be relevant to
brain functioning or associated with schizophrenia. These
findings should therefore be taken with considerable caution
at present, as it is too early to determine whether any of the
observed candidate CNVs will be confirmed as an important
schizophrenia risk factor. It is still possible that CNV
detection might just be a ‘fad’. Alternatively, the presence of
CNVs might eventually become important as a new-found
mechanism for complex genetic and psychiatric disorders.
Certainly, any CNV apparently associated with illness will
first need to be verified in large family-based studies to
determine whether it segregates with illness within families.
There has long been a debate as to whether all of schizo-
phrenia is inherited or whether a proportion of cases with no
apparent family history of illness could be sporadic [25].
Although environmental factors have been assumed to cause
sporadic cases, the alternative could certainly be de novo
germline mutations, such as CNVs.
When considering schizophrenia, we need to question
whether the CNV hypothesis is consistent with what we
know about the nature of the illness. Can multiple rare
variants be an explanation for a disease with worldwide and
unchanging incidence and prevalence rates, with sex differ-
ences in clinical presentation, with the characteristic delayed
age of onset, outcome and familial patterns, with the res-
ponse to neuroleptic drugs, with the consistent brain
structural anomalies across groups of patients worldwide
and with the many reported environmental risk factors?
Finally, is there any other disease model for this mechanism
that would be relevant to schizophrenia? We continue to
hope that the genetic basis for schizophrenia will be clarified
in the near future by novel technology and ultimately by
complete gene sequencing. Once the mechanism is estab-
lished there is optimism that new medications will be deve-
loped to target the relevant pathways uncovered.
A Ab bb br re ev vi ia at ti io on ns s
CNV, copy number variation; VCFS, Velocardiofacial
syndrome.
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